CONMED CORPORATION Unrecognized Tax Benefits
CONMED CORPORATION (CNMD) had Unrecognized Tax Benefits of $470.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefits · last filed 2026-02-17
- 2025-12-31: Unrecognized Tax Benefits $470.00K.
- 2024-12-31: Unrecognized Tax Benefits $1.15M.
- 2023-12-31: Unrecognized Tax Benefits $1.70M.
- 2022-12-31: Unrecognized Tax Benefits $200.00K.
| Period end | Unrecognized Tax Benefits |
|---|---|
| 2025-12-31 | $470.00K 10-K · filed 2026-02-17 |
| 2024-12-31 | $1.15M 10-K · filed 2026-02-17 |
| 2023-12-31 | $1.70M 10-K · filed 2026-02-17 |
| 2022-12-31 | $200.00K 10-K · filed 2026-02-17 |
| 2021-12-31 | $200.00K 10-K · filed 2025-02-18 |
| 2020-12-31 | $200.00K 10-K · filed 2024-02-28 |
| 2019-12-31 | $2.17M 10-K · filed 2023-02-21 |
| 2018-12-31 | $3.07M 10-K · filed 2022-02-22 |
| 2017-12-31 | $2.94M 10-K · filed 2021-02-22 |
| 2016-12-31 | $1.84M 10-K · filed 2020-02-24 |
| 2015-12-31 | $616.00K 10-K · filed 2019-02-25 |
| 2014-12-31 | $581.00K 10-K · filed 2018-02-26 |
| 2013-12-31 | $1.69M 10-K · filed 2017-02-27 |
| 2012-12-31 | $1.59M 10-K · filed 2016-02-23 |
| 2011-12-31 | $2.34M 10-K · filed 2015-02-23 |
| 2010-12-31 | $1.33M 10-K · filed 2014-02-24 |
| 2009-12-31 | $1.87M 10-K · filed 2013-02-25 |
| 2008-12-31 | $2.87M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |